Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression)

Journal of Autoimmunity

Volumn 31, Issue 4, 2008, Pages 393-398

  Katzav, Aviva ^a   Ben Ziv, Tal ^a   Chapman, Joab ^a,b   Blank, Miri ^a,b   Reichlin, Morris ^c   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Animal model; Anti P antibodies; Depression; Neuropsychiatric SLE; Olfaction

Indexed keywords

FLUOXETINE; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; RIBOSOMAL PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; AROMA; CINNAMON; CONTROLLED STUDY; DEPRESSION; FEMALE; FORCED SWIMMING TEST; IMMOBILIZATION; LEMON; MEASUREMENT; MOUSE; NONHUMAN; ODOR; PRIORITY JOURNAL; REVIEW; SMELLING; SMELLING DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AUTOANTIBODIES; CEREBRAL VENTRICLES; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; FLUOXETINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C3H; ODORS; OLFACTION DISORDERS; OLFACTORY PERCEPTION; RIBOSOMAL PROTEINS;

EID: 56549108923     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.09.002     Document Type: Review

References (41)

1. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 82 (2003) 299-308
2. Sherer Y., Gorstein A., Fritzler M.J., and Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34 (2004) 501-537
3. Borchers A.T., Aoki C.A., Naguwa S.M., Keen C.L., Shoenfeld Y., and Gershwin M.E. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 4 (2005) 329-344
4. Stojanovich L., Zandman-Goddard G., Pavlovich S., and Sikanich N. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 6 (2007) 421-426
5. Zandman-Goddard G., Chapman J., and Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36 (2007) 297-315
6. Conti F., Alessandri C., Bompane D., Bombardieri M., Spinelli F.R., Rusconi A.C., et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 6 (2004) R366-R372
7. Hanly J.G., Hong C., Smith S., and Fisk J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 42 (1999) 728-734
8. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., and Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7 (2001) 1189-1193
9. Katzav A., Solodeev I., Brodsky O., Chapman J., Pick C.G., Blank M., et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 56 (2007) 938-948
10. Kowal C., Degiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 103 (2006) 19854-19859
11. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12 (2003) 436-442
12. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 11 (2002) 736-743
13. Ziporen L., Polak-Charcon S., Korczyn D.A., Goldberg I., Afek A., Kopolovic J., et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 11 (2004) 67-75
14. Elkon K.B., Bonfa E., and Brot N. Antiribosomal antibodies in systemic lupus erythematosus. Rheum Dis Clin North Am 18 (1992) 377-390
15. Bonfa E., Golombek S.J., Kaufman L.D., Skelly S., Weissbach H., Brot N., et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317 (1987) 265-271
16. Toubi E., and Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 6 (2007) 119-125
17. Arnett F.C., Reveille J.D., Moutsopoulos H.M., Georgescu L., and Elkon K.B. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 39 (1996) 1833-1839
18. Schneebaum A.B., Singleton J.D., West S.G., Blodgett J.K., Allen L.G., Cheronis J.C., et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 90 (1991) 54-62
19. Eber T., Chapman J., and Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?. Lupus 14 (2005) 571-575
20. Pause B.M., Miranda A., Goder R., Aldenhoff J.B., and Ferstl R. Reduced olfactory performance in patients with major depression. J Psychiatr Res 35 (2001) 271-277
21. Fujiwara R., Komori T., Noda Y., Kuraoka T., Shibata H., Shizuya K., et al. Effects of a long-term inhalation of fragrances on the stress-induced immunosuppression in mice. Neuroimmunomodulation 5 (1998) 318-322
22. Kiecolt-Glaser J.K., Graham J.E., Malarkey W.B., Porter K., Lemeshow S., and Glaser R. Olfactory influences on mood and autonomic, endocrine, and immune function. Psychoneuroendocrinology 33 (2008) 328-339
23. Komori T., Fujiwara R., Tanida M., and Nomura J. Potential antidepressant effects of lemon odor in rats. Eur Neuropsychopharmacol 5 (1995) 477-480
24. Komori T., Fujiwara R., Tanida M., Nomura J., and Yokoyama M.M. Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation 2 (1995) 174-180
25. Koscec M., Koren E., Wolfson-Reichlin M., Fugate R.D., Trieu E., Targoff I.N., et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 159 (1997) 2033-2041
26. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229 (1977) 327-336
27. Becker M., Lavie V., Cohen-Kupiec R., and Solomon B. Intranasal immunization with phage-single-chain antibodies against EFRH, improves memory, attenuates hyposmia and brain pathology of PDAPP Tg mice. Neurodegener Dis 4 (2007) 251
28. Kelly J.P., Wrynn A.S., and Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74 (1997) 299-316
29. Leonard B.E., and Tuite M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 22 (1981) 251-286
30. Lumia A.R., Teicher M.H., Salchli F., Ayers E., and Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 587 (1992) 181-185
31. Song C., and Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29 (2005) 627-647
32. Roche M., Harkin A., and Kelly J.P. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology 32 (2007) 1312-1320
33. van Riezen H., Schnieden H., and Wren A.F. Olfactory bulb ablation in the rat: behavioural changes and their reversal by antidepressant drugs. Br J Pharmacol 60 (1977) 521-528
34. Komori T., Fujiwara R., Tanida M., and Nomura J. Application of fragrances to treatments for depression. Nihon Shinkei Seishin Yakurigaku Zasshi 15 (1995) 39-42
35. Koren E., Reichlin M.W., Koscec M., Fugate R.D., and Reichlin M. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 89 (1992) 1236-1241
36. Stafford H.A., Chen A.E., Anderson C.J., Paul A.G., Wyatt E.L., Lee L.A., et al. Anti-ribosomal and 'P-peptide'-specific autoantibodies bind to T lymphocytes. Clin Exp Immunol 109 (1997) 12-19
37. Alcocer-Varela J., Aleman-Hoey D., and Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1 (1992) 111-117
38. Svenungsson E., Andersson M., Brundin L., van Vollenhoven R., Khademi M., Tarkowski A., et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 60 (2001) 372-379
39. Trysberg E., Blennow K., Zachrisson O., and Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 6 (2004) R551-R556
40. George-Chandy A., Trysberg E., and Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with SLE; relationship to neuropsychiatric symptoms. Arthritis Res Ther 10 (2008) R97
41. Tanne D., Katzav A., Beilin O., Grigoriadis N.C., Blank M., Pick C.G., et al. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis 30 (2008) 56-64